ATE452190T1 - Verfahren zur isolierung und reinigung von g-csf - Google Patents

Verfahren zur isolierung und reinigung von g-csf

Info

Publication number
ATE452190T1
ATE452190T1 AT95119327T AT95119327T ATE452190T1 AT E452190 T1 ATE452190 T1 AT E452190T1 AT 95119327 T AT95119327 T AT 95119327T AT 95119327 T AT95119327 T AT 95119327T AT E452190 T1 ATE452190 T1 AT E452190T1
Authority
AT
Austria
Prior art keywords
csf
genetically engineered
isolation
purification
animals
Prior art date
Application number
AT95119327T
Other languages
English (en)
Inventor
Thomas C Boone
Allan L Miller
Jeffrey W Andresen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE452190T1 publication Critical patent/ATE452190T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Filling Or Discharging Of Gas Storage Vessels (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Accommodation For Nursing Or Treatment Tables (AREA)
AT95119327T 1988-05-13 1989-05-12 Verfahren zur isolierung und reinigung von g-csf ATE452190T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19385788A 1988-05-13 1988-05-13
US34801189A 1989-05-09 1989-05-09

Publications (1)

Publication Number Publication Date
ATE452190T1 true ATE452190T1 (de) 2010-01-15

Family

ID=26889429

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95119327T ATE452190T1 (de) 1988-05-13 1989-05-12 Verfahren zur isolierung und reinigung von g-csf

Country Status (12)

Country Link
US (1) US5849883A (de)
EP (2) EP0347041A3 (de)
JP (1) JP2796388B2 (de)
KR (1) KR0133561B1 (de)
AT (1) ATE452190T1 (de)
AU (3) AU636127B2 (de)
DE (1) DE68929566D1 (de)
DK (1) DK175245B1 (de)
FI (1) FI900178A0 (de)
NO (1) NO300217B1 (de)
NZ (1) NZ229098A (de)
WO (1) WO1989010932A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5718893A (en) * 1984-04-15 1998-02-17 Foster; Preston F. Use of G-CSF to reduce acute rejection
KR0133561B1 (ko) 1988-05-13 1998-04-21 스티븐 엠. 오드레 과립구 군체 자극인자의 정제방법
AU641949B2 (en) * 1989-10-10 1993-10-07 Amgen, Inc. Compositions and methods for treating or preventing infections in canine and feline animals
GB9107846D0 (en) * 1990-04-30 1991-05-29 Ici Plc Polypeptides
US5336488A (en) * 1991-08-07 1994-08-09 American Cyanamid Company Method of treating or preventing mastitis in animals with involuting mammary glands by administering recombinant cytokines
US5536495A (en) * 1994-04-15 1996-07-16 Foster; Preston F. Use of G-CSF to reduce acute rejection
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
WO1996006170A1 (en) * 1994-08-19 1996-02-29 Embrex, Inc. Method of treating birds with avian myelomonocytic growth factor
US20030053982A1 (en) 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU6028396A (en) 1995-06-07 1996-12-30 Amgen, Inc. Ob protein compositions and method
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US6979442B1 (en) 1998-08-17 2005-12-27 Pfizer Inc. Stabilized protein compositions
ATE260674T1 (de) * 1998-08-17 2004-03-15 Pfizer Prod Inc Stabilisierte proteinzusammensetzung
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
US6646110B2 (en) 2000-01-10 2003-11-11 Maxygen Holdings Ltd. G-CSF polypeptides and conjugates
US6831158B2 (en) 2000-01-10 2004-12-14 Maxygen Holdings Ltd. G-CSF conjugates
US6555660B2 (en) 2000-01-10 2003-04-29 Maxygen Holdings Ltd. G-CSF conjugates
EP1129720B1 (de) 2000-02-29 2004-06-23 Pfizer Products Inc. Stabilisierter Granulozyten-Kolonie-stimulierender Faktor
MXPA03002045A (es) 2000-09-08 2003-07-24 Amgen Inc Composiciones analogas de factor estimulador de colonias de granulocitos y metodos para su elaboracion.
EP1425304B9 (de) 2001-07-11 2010-09-08 Maxygen, Inc. G-csf konjugate
SI21102A (sl) * 2001-12-19 2003-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
KR100508358B1 (ko) 2002-03-20 2005-08-17 주식회사 바이오폴리메드 생체적합성 고분자가 시스테인 잔기에 화학양론적으로 결합된 ｇ-ｃｓｆ의 제조 방법
AU2002345829A1 (en) * 2002-06-24 2004-01-06 Dr. Reddy's Laboratories Ltd. Process for preparing g-csf
WO2005025593A2 (en) * 2003-05-09 2005-03-24 Schering Aktiengesellschaft Treatment of inflammatory respiratory diseases
US7220407B2 (en) 2003-10-27 2007-05-22 Amgen Inc. G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
ATE471340T1 (de) 2004-02-11 2010-07-15 Amylin Pharmaceuticals Inc Peptide der amylin familie, verfahren zu deren herstellung und verwendung
US8603969B2 (en) 2004-02-11 2013-12-10 Amylin Pharmaceuticals, Llc Pancreatic polypeptide family motifs and polypeptides comprising the same
NZ579621A (en) 2004-02-11 2011-03-31 Amylin Pharmaceuticals Inc Hybrid polypeptides with selectable properties
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
CA2580991A1 (en) 2004-10-08 2006-04-20 Amylin Pharmaceuticals, Inc. Amylin family polypeptide-6 (afp-6) analogs and methods of making and using them
AU2005306894B2 (en) 2004-11-05 2011-11-24 Northwestern University Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
EP2360180A3 (de) 2004-12-13 2012-02-08 Amylin Pharmaceuticals Inc. Motive der bauchspeicheldrüsen-polypeptid familie, polypeptide und methoden und verwendung derselben
KR20070115947A (ko) 2005-02-11 2007-12-06 아밀린 파마슈티칼스, 인크. 선택가능한 특성들을 가지는 ｇｉｐ 유사체 및 하이브리드폴리펩타이드
WO2007022123A2 (en) 2005-08-11 2007-02-22 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
KR20080027291A (ko) 2005-06-01 2008-03-26 맥시겐 홀딩스 엘티디 피이지화된 지-씨에스에프 폴리펩타이드 및 그 제조방법
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
KR100735784B1 (ko) * 2005-07-20 2007-07-06 재단법인 목암생명공학연구소 인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
EP2330125A3 (de) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybridpolypeptide mit auswählbaren Eigenschaften
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
US9176145B2 (en) 2006-07-21 2015-11-03 Femalon S.P.R.L. Kit for predicting implantation success in assisted fertilization
WO2008116470A1 (en) * 2007-03-26 2008-10-02 Drugrecure Aps Enhancing pulmonary host defence via administration of granulocyte- colony stimulating factor
MX2010002448A (es) 2007-08-27 2010-10-04 Biogenerix Ag Formulacion liquida del g-csf conjugado.
CN102089319B (zh) 2008-05-08 2013-11-13 味之素株式会社 蛋白质的重折叠方法
CN102159230A (zh) 2008-07-23 2011-08-17 Ambrx公司 经修饰的牛g-csf多肽和其用途
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
EP3366692A1 (de) 2009-06-22 2018-08-29 Amgen, Inc Proteinneufaltung mit einem chemisch gesteuerten redoxzustand
AU2010266093B2 (en) 2009-06-25 2013-06-27 Amgen Inc. Capture purification processes for proteins expressed in a non-mammalian system
WO2011033068A1 (en) 2009-09-18 2011-03-24 Novo Nordisk A/S Long-acting y2 receptor agonists
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
BR112012015597A2 (pt) 2009-12-21 2017-01-31 Ambrx Inc peptídeos de somatotropina suínos modificados e seus usos
CN102892780B (zh) 2010-03-17 2015-07-29 通益制药有限公司 获得生物活性的重组人g-csf的方法
RU2487885C2 (ru) * 2010-07-20 2013-07-20 Зао "Биокад" Способ крупномасштабного получения, выделения и очистки рекомбинантного гранулоцитарного колониестимулирующего фактора человека
TWI480288B (zh) 2010-09-23 2015-04-11 Lilly Co Eli 牛顆粒細胞群落刺激因子及其變體之調配物
MX363465B (es) 2011-02-18 2019-03-25 Kythera Biopharmaceuticals Inc Tratamiento de la grasa submental.
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
HUP1200172A2 (en) * 2012-03-19 2013-10-28 Richter Gedeon Nyrt Methods for refolding g-csf from inclusion bodies
US20150141336A1 (en) 2012-05-29 2015-05-21 Novo Nordisk A/S Pancreatic Peptide Compounds and Use
US9982012B2 (en) 2013-03-29 2018-05-29 Dr. Reddy's Laboratories Limited Refolding of granulocyte colony stimulating factor
AU2018348138A1 (en) * 2017-10-11 2020-04-23 Ambrx, Inc. Porcine G-CSF variants and their uses
WO2020234742A1 (en) * 2019-05-20 2020-11-26 Lupin Limited Granulocyte colony stimulating factor purification
EP3996828A4 (de) * 2019-07-09 2023-09-06 Tanvex Biopharma Usa, Inc. Temperaturgesteuerte reinigung von granulozyten-kolonie stimulierendem faktor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2438821A1 (fr) * 1978-10-13 1980-05-09 France Etat Dispositif d'allumage a fil chaud de securite
US4618600A (en) * 1984-04-19 1986-10-21 Biotechnology Research Associates, J.V. Novel polypeptide diuretic/vasodilators
JPS6145010A (ja) * 1984-08-08 1986-03-04 Setsuji Umezaki 埋立地の造成方法
JPH0615477B2 (ja) * 1985-02-08 1994-03-02 中外製薬株式会社 感染防禦剤
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4721420A (en) * 1985-09-03 1988-01-26 Arthur D. Little, Inc. Pipeline transportation of coarse coal-liquid carbon dioxide slurry
JPH0618781B2 (ja) * 1986-10-18 1994-03-16 中外製薬株式会社 感染症治療剤
AU621051B2 (en) * 1987-04-28 1992-03-05 Amgen, Inc. Method for purifying granulocyte-macrophage colony stimulating factor
EP0313343B2 (de) * 1987-10-23 2003-07-23 Schering Corporation Verfahren zur Proteinreinigung
KR0133561B1 (ko) 1988-05-13 1998-04-21 스티븐 엠. 오드레 과립구 군체 자극인자의 정제방법

Also Published As

Publication number Publication date
EP0719860A1 (de) 1996-07-03
KR0133561B1 (ko) 1998-04-21
EP0347041A2 (de) 1989-12-20
NO900185D0 (no) 1990-01-12
JP2796388B2 (ja) 1998-09-10
AU636127B2 (en) 1993-04-22
EP0719860B1 (de) 2009-12-16
DE68929566D1 (de) 2010-01-28
US5849883A (en) 1998-12-15
NO900185L (no) 1990-03-12
NO300217B1 (no) 1997-04-28
EP0347041A3 (de) 1990-11-22
FI900178A7 (fi) 1990-01-12
DK9290D0 (da) 1990-01-12
NZ229098A (en) 1992-10-28
AU4781290A (en) 1990-11-15
JPH02504521A (ja) 1990-12-20
AU4197293A (en) 1993-10-28
KR900701824A (ko) 1990-12-04
DK9290A (da) 1990-03-09
DK175245B1 (da) 2004-07-19
FI900178A0 (fi) 1990-01-12
WO1989010932A1 (en) 1989-11-16
AU4197393A (en) 1993-10-28
AU661172B2 (en) 1995-07-13

Similar Documents

Publication Publication Date Title
ATE452190T1 (de) Verfahren zur isolierung und reinigung von g-csf
ES8507535A1 (es) Acidos 7-amino-1-ciclopropil-6,8-difluor-1,4-dihidro-4-oxo-quinolincarboxilicos
MY130047A (en) Methods and compositions employing certain lysozymes and endoglycosidases
GR79989B (de)
AU579595B2 (en) Enzyme-resistant immunomodulatory peptides
DK16890A (da) Antiviral eller antibakteriel forbindelse og frem gangsmaade til anvendelse heraf
EP0308020A3 (de) 5-(Aryl und Heteroaryl)-6-(Aryl und Heteroaryl)-1,2-dihydro-2-oxo-3-pyridincarbonsäure und Derivate davon
ATE73342T1 (de) Polypeptid-wachstumsfaktor aus milch.
ATE120795T1 (de) Ärztliche antimikrobielle polypeptide, deren verwendung und verfahren zur herstellung.
DK534288A (da) Hidtil ukendt proces
RU94020410A (ru) Способ лечения или профилактики рвоты у млекопитающих и человека с использованием некоторых хинуклидиновых, пиперидиновых, азанорборнановых, этилендиаминовых производных и родственных им соединений
DK471386A (da) Farmaceutisk komposition til behandling af leukopeni
SE8803071D0 (sv) Bakteriebehandling for att bevara hokvalitet genom att tillegga genius bacillus mikroorganismer
ATE92717T1 (de) Verfahren zur verbesserung der wirksamkeit von insektentoxinen.
DE69833876D1 (de) Zusammensetzungen und methoden zur zielgerichteten abgabe von biologisch aktivenfaktoren
AU2696584A (en) Pharmaceutical compositions of anti-pancreatic inflammatory effect
GB9723945D0 (en) Tissue cement
DE69429521D1 (de) Zusammensetzung und verfahren zur stimulation der reproduzierenden leistung
DE69827163D1 (de) Phytase zur vorbeugung oder behandlung von mastitis
ZA871140B (en) Synergistic chemical compositions for treating salmonellosis
ES8707955A1 (es) Un procedimiento para la preparacion pirazolidinonas biciclicas'
NZ222855A (en) Bacterial composition used as an animal treatment
ATE68742T1 (de) Zusammensetzungen, bestimmt zur holzbehandlung und verfahren zur holzbehandlung.
FI880801A7 (fi) Puun käsittelyyn tarkoitetut koostumukset ja menetelmät puun käsittelemiseksi.
MY110041A (en) Composition and method of treating hepatitis c

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties